We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
DWTX

Price
4.90
Stock movement up
+0.10 (2.08%)
Company name
Dogwood Therapeutics, Inc.
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
6.53M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-21.60%
3 year return
-64.05%
5 year return
-
10 year return
-
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

DWTX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open4.71
Daily high5.00
Daily low4.71
Daily Volume47K
All-time high219.25
1y analyst estimate13.83
Beta1.94
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
DWTXS&P500
Current price drop from All-time high-97.77%-3.04%
Highest price drop-99.16%-56.47%
Date of highest drop18 Nov 20249 Mar 2009
Avg drop from high-70.75%-11.04%
Avg time to new high67 days12 days
Max time to new high692 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
DWTX (Dogwood Therapeutics, Inc.) company logo
Marketcap
6.53M
Marketcap category
Small-cap
Description
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Employees
12
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...